Advertisement

Advertisement

CATX Stock Latest News

Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data

Company AnnouncementsPerspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

PremiumThe Fly

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

10d ago

Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline

PremiumCompany Announcements

Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline

28d ago

Reiterating Buy on Perspective Therapeutics: Strong Cash Runway, Improving Earnings Outlook, and Clinical Milestones Support $13 DCF Valuation

PremiumRatings

Reiterating Buy on Perspective Therapeutics: Strong Cash Runway, Improving Earnings Outlook, and Clinical Milestones Support $13 DCF Valuation

1M ago

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

PremiumThe Fly

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

1M ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

PremiumThe FlyPerspective Therapeutics price target raised to $8 from $7 at UBS

1M ago

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

The Fly

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

1M ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

The Fly

Perspective Therapeutics price target raised to $8 from $7 at UBS

1M ago

Perspective Therapeutics Reports 2025 Results, Highlights Pipeline Progress

PremiumCompany Announcements

Perspective Therapeutics Reports 2025 Results, Highlights Pipeline Progress

1M ago

Perspective Therapeutics initiated with an Overweight at Piper Sandler

PremiumThe Fly

Perspective Therapeutics initiated with an Overweight at Piper Sandler

2M ago

Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside

PremiumRatings

Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside

2M ago

Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline

PremiumCompany Announcements

Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline

3M ago

Midday Fly By: Disney slips despite Q1 beat, Devon to combine with Coterra

PremiumThe FlyMidday Fly By: Disney slips despite Q1 beat, Devon to combine with Coterra

3M ago

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

The Fly

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

3M ago

Perspective Therapeutics Highlights Progress in Radiopharmaceutical Pipeline

Company Announcements

Perspective Therapeutics Highlights Progress in Radiopharmaceutical Pipeline

3M ago

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

PremiumThe Fly

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

3M ago

Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline

PremiumCompany Announcements

Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline

4M ago

Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target

PremiumRatings

Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target

4M ago

Perspective Therapeutics outlines 2026 clinical and manufacturing priorities

PremiumCompany Announcements

Perspective Therapeutics outlines 2026 clinical and manufacturing priorities

4M ago

Perspective Therapeutics provides business updates, strategic priorities

PremiumThe FlyPerspective Therapeutics provides business updates, strategic priorities

4M ago

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data

Company Announcements

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data

4M ago

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

The Fly

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >